Xeris Biopharma Holdings Future Growth
Future criteria checks 4/6
Xeris Biopharma Holdings is forecast to grow earnings and revenue by 62.1% and 14.9% per annum respectively while EPS is expected to grow by 63.2% per annum.
Key information
62.1%
Earnings growth rate
63.2%
EPS growth rate
| Pharmaceuticals earnings growth | 22.9% |
| Revenue growth rate | 14.9% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 27 Mar 2024 |
Recent future growth updates
Recent updates
Xeris Biopharma: Checking-In On One Of My 'Top Ideas'
Mar 30Analysts Are Updating Their Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Estimates After Its Full-Year Results
Mar 09
Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Shares Climb 26% But Its Business Is Yet to Catch Up
Mar 06Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Fly 32% But Investors Aren't Buying For Growth
Jan 05Xeris Pharmaceuticals Q2 2022 Earnings Preview
Aug 09Xeris amends commercial terms for hypoglycemia therapy as partner inks buyout deal
Aug 01Xeris Biopharma: Q1 Earnings Reveal Path To Breakeven
May 21Xeris Continues To Execute And Build Long-Term Value Potential
Feb 22Xeris Biopharma: Market Is Snubbing The Strongbridge Acquisition
Dec 20Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 259 | 11 | N/A | 65 | 5 |
| 12/31/2025 | 219 | -27 | N/A | 2 | 6 |
| 12/31/2024 | 184 | -56 | N/A | -19 | 6 |
| 12/31/2023 | 164 | -62 | -49 | -47 | N/A |
| 9/30/2023 | 153 | -62 | -73 | -71 | N/A |
| 6/30/2023 | 134 | -71 | -76 | -74 | N/A |
| 3/31/2023 | 121 | -78 | -81 | -81 | N/A |
| 12/31/2022 | 110 | -95 | -103 | -103 | N/A |
| 9/30/2022 | 99 | -133 | -116 | -116 | N/A |
| 6/30/2022 | 80 | -137 | -121 | -121 | N/A |
| 3/31/2022 | 63 | -138 | -121 | -120 | N/A |
| 12/31/2021 | 50 | -123 | -97 | -96 | N/A |
| 9/30/2021 | 35 | -94 | -79 | -77 | N/A |
| 6/30/2021 | 34 | -84 | -73 | -72 | N/A |
| 3/31/2021 | 27 | -80 | -76 | -76 | N/A |
| 12/31/2020 | 20 | -91 | -81 | -81 | N/A |
| 9/30/2020 | 15 | -102 | -100 | -99 | N/A |
| 6/30/2020 | 6 | -119 | -114 | -113 | N/A |
| 3/31/2020 | 4 | -129 | -113 | -112 | N/A |
| 12/31/2019 | 3 | -126 | -105 | -104 | N/A |
| 9/30/2019 | 2 | -113 | -94 | -93 | N/A |
| 6/30/2019 | 2 | -95 | -80 | -78 | N/A |
| 3/31/2019 | 2 | -73 | -71 | -70 | N/A |
| 12/31/2018 | 2 | -60 | -58 | -56 | N/A |
| 9/30/2018 | 2 | -49 | -49 | -47 | N/A |
| 6/30/2018 | 2 | -42 | -37 | -37 | N/A |
| 3/31/2018 | 1 | -34 | -30 | -29 | N/A |
| 12/31/2017 | 2 | -27 | -25 | -25 | N/A |
| 12/31/2016 | 1 | -13 | N/A | -16 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: XERS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).
Earnings vs Market: XERS is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: XERS is expected to become profitable in the next 3 years.
Revenue vs Market: XERS's revenue (14.9% per year) is forecast to grow faster than the US market (8.1% per year).
High Growth Revenue: XERS's revenue (14.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if XERS's Return on Equity is forecast to be high in 3 years time